Literature DB >> 16432842

Reclassification of oligoastrocytomas by loss of heterozygosity studies.

Marica Eoli1, Lorena Bissola, Maria Grazia Bruzzone, Bianca Pollo, Carmelo Maccagnano, Tiziana De Simone, Lorella Valletta, Antonio Silvani, D Bianchessi, Giovanni Broggi, Amerigo Boiardi, Gaetano Finocchiaro.   

Abstract

Oligoastrocytomas (OAs) are WHO grade II or III tumors composed of a mixture of 2 neoplastic cell types morphologically resembling the cells in oligodendrogliomas and diffuse astrocytomas. Investigations on the genetic profile of OAs may yield important information for their classification and help for their clinical management. We have studied, in 94 OAs (46 WHO grade II and 48 WHO grade III), the patterns of loss of heterozygosity (LOH) of 4 genomic regions: 1p, 19q, 17p and 10q. Results were as follows: LOH 1p was present in 46% of the tumors; LOH 19q in 45%; LOH 17p in 22%; LOH 10q in 16%. LOH 1p and 19q were associated in 32%, other LOH associations were rare (<3%). Patients had a median follow-up of 30 months. Patients without LOH on 1p had shorter progression free survival than patients with LOH on 1p: 30 vs. 132 months, p < 0.0001. MRI indicated that tumors without LOH on 1p were often temporal (p < 0.02), and showed signal inhomogeneity on T1 and T2 images (p < 0.02) and contrast enhancement (p < 0.04). Thus, LOH on 1p identifies two subgroups of OAs. OAs without LOH on 1p behave like WHO grade II or III diffuse astrocytomas: they have shorter survival, MRI characteristics implying malignancy and genetic alterations associated with tumor progression. OAs with LOH on 1p, on the other hand, behave like WHO grade II or III oligodendrogliomas with 1p loss: they are associated with longer survival and do not have MRI or genetic alterations associated with malignancy. These findings suggest that the definition of OAs or mixed gliomas could be reshaped in agreement with the genetic information.

Entities:  

Mesh:

Year:  2006        PMID: 16432842     DOI: 10.1002/ijc.21759

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

Review 2.  Genetics and imaging of oligodendroglial tumors.

Authors:  Jonathan R Ellenbogen; Carol Walker; Michael D Jenkinson
Journal:  CNS Oncol       Date:  2015-10-19

Review 3.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.

Authors:  Michael Jansen; Stephen Yip; David N Louis
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

5.  The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jonathan Hobbs; Stephanie Bortoluzzi; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

6.  Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?

Authors:  B A Campbell; D E Horsman; J Maguire; S Young; D Curman; R Ma; B Thiessen
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

7.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

8.  Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.

Authors:  Leonard Sunwoo; Seung Hong Choi; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Sun-Won Park; Chul-Ho Sohn; Jae-Kyung Won; Sung-Hye Park; Il Han Kim
Journal:  Neuroradiology       Date:  2015-08-01       Impact factor: 2.804

9.  1p/19q testing has no significance in the workup of glioblastomas.

Authors:  K H Clark; J L Villano; M N Nikiforova; R L Hamilton; C Horbinski
Journal:  Neuropathol Appl Neurobiol       Date:  2013-10       Impact factor: 8.090

10.  Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.

Authors:  Hao Zhou; Ken Chang; Harrison X Bai; Bo Xiao; Chang Su; Wenya Linda Bi; Paul J Zhang; Joeky T Senders; Martin Vallières; Vasileios K Kavouridis; Alessandro Boaro; Omar Arnaout; Li Yang; Raymond Y Huang
Journal:  J Neurooncol       Date:  2019-01-19       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.